Equities Analysts Offer Predictions for Alumis Q3 Earnings

Alumis Inc. (NASDAQ:ALMS) – Equities researchers at HC Wainwright issued their Q3 2024 EPS estimates for shares of Alumis in a research report issued on Thursday, October 17th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($2.27) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Alumis’ current full-year earnings is ($6.86) per share. HC Wainwright also issued estimates for Alumis’ Q4 2024 earnings at ($1.20) EPS, FY2024 earnings at ($11.42) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.24) EPS and FY2025 earnings at ($4.90) EPS.

Alumis (NASDAQ:ALMS) last announced its earnings results on Tuesday, August 13th. The company reported ($23.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($21.53).

A number of other brokerages have also commented on ALMS. Morgan Stanley assumed coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “overweight” rating and a $36.00 price target on the stock. Leerink Partners started coverage on shares of Alumis in a research note on Tuesday, July 23rd. They issued an “outperform” rating and a $29.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research note on Monday, August 19th. Leerink Partnrs upgraded shares of Alumis to a “strong-buy” rating in a report on Tuesday, July 23rd. Finally, Guggenheim initiated coverage on shares of Alumis in a report on Tuesday, July 23rd. They set a “buy” rating and a $32.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $28.00.

Alumis Trading Up 3.2 %

Shares of NASDAQ:ALMS opened at $12.98 on Monday. The business’s 50-day simple moving average is $11.66. Alumis has a one year low of $9.54 and a one year high of $13.53.

Institutional Trading of Alumis

Several institutional investors have recently added to or reduced their stakes in the company. Towerview LLC bought a new stake in shares of Alumis in the 2nd quarter valued at about $4,123,000. SR One Capital Management LP purchased a new stake in shares of Alumis in the 2nd quarter valued at $26,067,000. Ally Bridge Group NY LLC purchased a new stake in shares of Alumis in the 2nd quarter valued at $8,229,000. Yu Fan purchased a new stake in shares of Alumis in the 2nd quarter valued at $10,502,000. Finally, Millennium Management LLC purchased a new stake in shares of Alumis in the 2nd quarter valued at $3,376,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.